Compare DLR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLR | EW |
|---|---|---|
| Founded | 2004 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5B | 49.5B |
| IPO Year | 2004 | 2000 |
| Metric | DLR | EW |
|---|---|---|
| Price | $163.81 | $84.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 21 |
| Target Price | ★ $194.35 | $96.37 |
| AVG Volume (30 Days) | 2.0M | ★ 3.1M |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 240.80 | N/A |
| EPS | ★ 3.87 | 2.33 |
| Revenue | $5,841,036,000.00 | ★ $5,883,800,000.00 |
| Revenue This Year | $12.42 | $14.29 |
| Revenue Next Year | $10.65 | $9.68 |
| P/E Ratio | $42.25 | ★ $36.90 |
| Revenue Growth | 8.67 | ★ 10.60 |
| 52 Week Low | $129.95 | $65.94 |
| 52 Week High | $187.74 | $87.89 |
| Indicator | DLR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 48.32 |
| Support Level | $157.26 | $81.26 |
| Resistance Level | $161.09 | $86.10 |
| Average True Range (ATR) | 3.37 | 1.74 |
| MACD | 1.18 | -0.22 |
| Stochastic Oscillator | 91.68 | 48.87 |
Digital Realty owns and operates over 300 data centers worldwide. It has nearly 40 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to "cold shells," where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has deemphasized cold shells and now primarily provides higher-level service to tenants that outsource their related IT needs to Digital. The company operates as a real estate investment trust.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.